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Abstract: Therapy of hormone receptor positive breast cancer (BCa) generally targets estrogen
receptor (ER) function and signaling by reducing estrogen production or by blocking its interaction
with the ER. Despite good long-term responses, resistance to treatment remains a significant issue,
with approximately 40% of BCa patients developing resistance to ET. Mutations in the gene encoding
ERα, ESR1, have been identified in BCa patients and are implicated as drivers of resistance and
disease recurrence. Understanding the molecular consequences of these mutations on ER protein
levels and its activity, which is tightly regulated, is vital. ER activity is in part controlled via its
short protein half-life and therefore changes to its stability, either through mutations or alterations in
pathways involved in protein stability, may play a role in therapy resistance. Understanding these
connections and how ESR1 alterations could affect protein stability may identify novel biomarkers of
resistance. This review explores the current reported data regarding posttranslational modifications
(PTMs) of the ER and the potential impact of known resistance associated ESR1 mutations on ER
regulation by affecting these PTMs in the context of ET resistance.
Keywords: breast cancer; ESR1; proteasome; posttranslational modifications; endocrine therapy
1. Introduction
The estrogen receptor (ER) is the main downstream effector of its ligand estrogen and has
functions connected to the menstrual cycle, pregnancy, and lactation in females and in maintaining
cardiovascular, nervous, musculoskeletal, and immune system functioning [1]. There are two subtypes
of ER, namely ERα and ERβ, encoded by ESR1 and ESR2, respectively. These genes are located on
separate chromosomes, ESR1 at position 6q24-27 and ESR2 at 14q22-24 [2–4]. Whilst highly similar,
their ligand binding domains (LBD) differ, enabling specific physiological functions [1,5,6].
The ERα, a 66 kDa protein, is comprised of four domains, namely activation function 1 (AF-1),
DNA binding domain (DBD), the hinge region, and the LBD also known as AF-2 [1,7] (Figure 1).
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Figure 1. ERα functional domains. The ERα functional domains include; Activation Function 1 (AF-1) 
(purple), DNA Binding Domain (DBD) (blue), hinge (pink), Ligand Binding Domain (LBD) and AF-2 
(plum). 
Upon estrogen binding, ER forms homodimers (ERα/ERα or ERβ/ERβ) and heterodimers 
(ERα/ERβ) [8,9]. This review focuses on ESR1 encoding ERα, referred to as ER henceforth. Following 
dimerisation, ER translocates to the nucleus and regulates transcription through estrogen response 
element (ERE) binding within target gene promoters (Figure 2, “genomic function”). 
 
Figure 2. Estrogen Receptor Signalling and ER Targeting Treatment. Aromatase converts androgens 
to estrogens, Estrogen receptor binds estrogen, Dimerisation, Post translational modification, Nuclear 
localisation, Coactivator binding and target gene (PGR, c-Myc, GREB1) transcription, Addition of 
ubiquitin by E1, E2 & E3 ligases, Degradation by the 26S proteasome. Aromatase Inhibitors (AIs) 
inhibit the enzyme aromatase, Selective Estrogen Receptor Degraders (SERDs) and Selective Estrogen 
Receptor Modifiers (SERMs) prevent estrogen binding. 
Alternatively, ER may crosstalk with the PI3K-AKT-mTOR or MAPK pathways, in a “non-
genomic” manner (see below), in both scenarios promoting cell proliferation and suppressing 
apoptosis [10]. 
Approximately 75% of BCa express ER, which promotes oncogenesis. As such, the ER is a 
common target for BCa treatment using endocrine therapies (ETs) including tamoxifen, fulvestrant, 
and aromatase inhibitors (AIs) [11] (Figure 2). Tamoxifen is known as a selective ER modifier (SERM) 
Figure 1. ERα functional domains. The ERα functional domains include; Activation Function 1 (AF-1)
(purple), DNA Binding Domain (DBD) (blue), hinge (pink), Ligand Binding Domain (LBD) and AF-2 (plum).
Upon estrogen binding, ER forms homodimers (ERα/ERα or ERβ/ERβ) and heterodimers
(ERα/ERβ) [8,9]. This review focuses on ESR1 encoding ERα, referred to as ER henceforth. Following
dimerisation, ER translocates to the nucleus an regulates transcription through estrog n response
element (ERE) binding within targ t gene promoters (Figure 2, “genomic functio ”).
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Figure 2. Estrogen Receptor Signalling and ER Targeting Treatment. Aromatase converts androgens to
estrogens, Estrogen receptor binds estrogen, Dimerisation, Post translational modification, Nuclear
localisation, Coactivator binding and target gene (PGR, c-Myc, GREB1) transcription, Addition of
ubiquitin by E1, E2 & E3 ligases, Degradation by the 26S proteasome. Aromatase Inhibitors (AIs)
inhibit the enzyme aromatase, Selective Estrogen Receptor Degraders (SERDs) and Sel c ive Estrogen
Receptor Modifiers (SERMs) prevent str binding.
Alternatively, ER may crosstalk with the PI3K-AKT-mTOR or MAPK pathways, in a “non-genomic”
manner (see below), in both scenarios promoting cell proliferation and suppressing apoptosis [10].
Approximately 75% of BCa express ER, which promotes oncogenesis. As such, the ER is a
common target for BCa treatment using endocrine therapies (ETs) including tamoxifen, fulvestrant,
and aromatase inhibitors (AIs) [11] (Figure 2). Tamoxifen is known as a selective ER modifier (SERM)
and fulvestr t as a selective ER degrader (SERD) [12]. SERMs competitively bind ER forming an
inactive complex, by preventing coactivator interactions [12–15]. SERDs also competitively bind ER;
however, their binding targets the receptor for proteasomal d gradatio [16–18]. AIs are a group of
drugs that pr vent the synthesis of the estrogen, through inhibition of aromatase [19–21]. AIs include
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letrozole, anastrozole, and exemestane. Whilst these treatments are initially effective for many ER
positive BCa patients, resistance remains a significant issue.
Resistance to ET is common, approximately 30% of BCa patients acquire resistance [22,23].
ESR1 mutations have been identified in ET resistant BCa tumours. Several ESR1 mutations have
been functionally characterised and confer key attributes associated with ET resistance, indicating
mechanistic roles in resistance such as estrogen independence, increased transcription of ER target
genes like PGR (progesterone receptor), GREB1 (growth regulation by estrogen in breast cancer 1),
and MYC (c-myc), and increased proliferation and altered ER conformation [24,25] (Figure 2).
Since a major control of ER activity is through regulation of its half-life, changes to ER stability may
influence sensitivity to ET. For example, posttranslational modifications (PTMs) and ESR1 mutations
causing amino acid substitutions at PTM sites may influence ER stability, and ultimately activity.
This review explores the link between ER PTMs and turnover, with a focus on ET resistance associated
ESR1 mutations and their effects.
2. Estrogen Receptor Signaling
The estrogen/ER complex can result in activation of two distinct types of signaling pathways,
the genomic and non-genomic. In the genomic pathway, the ER regulates gene transcription through
direct binding of its DBD to promotors containing an ERE, or through interactions with other
transcription factors at promoter regions [9,26]. The non-genomic pathway, however, enables rapid
signaling through bidirectional crosstalk with PI3K-AKT-mTOR and MAPK pathways. These pathways
are frequently upregulated in BCa and enable signaling in an estrogen independent manner [27–29].
Several kinases from these pathways phosphorylate the ER at various sites, mediating ER stability,
localization, and transactivational capacity, discussed in detail below [30,31]. Further, these pathways
may contribute to ET resistance through phosphorylation at key sites, even in the absence of estrogen [32–37].
Additionally, crosstalk between ER and PI3K-AKT-mTOR and MAPK pathways is bidirectional. The ER
may activate these pathways through interaction with modulator of non-genomic action of estrogen
receptor (MNAR) scaffold protein and subsequent SRC activation [38,39]. Ultimately, these pathways
promote cell cycle progression through increased expression of cyclin D1, and suppress apoptosis [38,40].
Understanding these interactions is important as the PI3K and MAPK pathways are frequently active
in ET resistant BCa and contribute to ET resistance [27–29].
The ER is regulated by a range of PTMs including ubiquitylation, SUMOylation, phosphorylation,
palmitoylation, acetylation, methylation and glycosylation [41–44]. These modifications are proposed
to regulate the activity, stability, and interactions of ER with other proteins or DNA, and ESR1 mutations
may influence PTMs and hence ER stability and function (Figure 3).
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Figure 3. Post translational modifications of ERα. The ERα functional domains include: Activation
Function 1 (AF-1) (purple), DNA Binding Domain (DBD) (blue), hinge (pink), Ligand Binding Domain
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2.1. Estrogen Receptor Turnover
Whilst ER is produced through transcription and protein synthesis, changes to ER degradation
kinetics is the major factor determining ER levels. In BCa, there is an imbalance between the rate
of transcription, synthesis and degradation of the ER leading to increased ER stability and thus
activity [45]. The half-life of the ER differs significantly depending on estrogen exposure. Generally,
the ER half-life is 3–5 h [46] and estrogen presence can reduce the half-life to just 1 h [47]. However,
persistent estrogen exposure causes relative ER stability. In fact, in MCF-7 cells exposed to estrogen
for 72 h, ER half-life was increased to 6 h, due to the decreased rate of proteolysis associated with
p-S118 [48].
2.2. Degradation by the Ubiquitin Proteasome Pathway
Several studies have shown increased ER stability in the presence of the proteasome inhibitor, MG132,
indicating that degradation by the ubiquitin–proteasome system (UPS) regulates ER stability [47,49–51].
Degradation of the ER occurs predominantly through the UPS, which relies on ER ubiquitylation by
ubiquitin activating enzymes (E1) and ubiquitin conjugating enzymes (E2). Conversely, the ER may
be protected from degradation through the activity of ubiquitin ligases (E3), which remove ubiquitin
from the ER.
Ubiquitin conjugation or removal occurs on lysine residues, and mutations resulting in an
exchange, either of such lysines or of amino acids affecting the accessibility of important lysines, may
therefore alter the protein’s stability. Additionally, some UPS proteins act as coactivators of nuclear
receptors and promote downstream gene transcription [16,44,52,53]. For example, ubiquitin ligase
E3A (E6-AP) acts as an ER coactivator and increases gene transcription [16,53].
3. Post Translational Modifications
3.1. Ubiquitylation
The ER is regulated by both monoubiquitylation and polyubiquitylation and these serve distinct
functions. Monoubiquitylation increases the stability and transcriptional activity of the receptor, whilst
further addition of ubiquitin, polyubiquitylation, targets the protein for degradation by the UPS [53].
Some proteins have an inhibitory effect on ubiquitylation which leads to increased stability of the
ER associated with ET resistance, broadly classified as coactivators, E3 ligases, kinases and scaffold
proteins [45].
The K303 site is affected by an ESR1 mutation, K303R, and is a reported ubiquitination target.
K302 and K303 have been implicated in ER stability and its nuclear localisation [52] (Table 1).
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Table 1. ER Posttranscriptional Modification Sites and Effects of Mutations.
Site Posttranslational Modification (Mediator) Effect ESR1 Mutations # ET Resistant Frequency Functionally Tested
Y52 Phosphorylation(c-Abl)
Increased gene transactivation,
increased DNA binding and
dimerisation, rapid cell growth and
increased invasive capacity [54]
None N/A N/A N/A
S104 Phosphorylation(Cyclin A/CDK2, MAPK ERK1/2, GSK3β)
Increased gene transactivation,
tamoxifen sensitivity, ER stability in
absence of E2 [31,55]
None N/A N/A N/A
S106 Phosphorylation(MAPK ERK1/2, GSK3β)
Increased gene transactivation,
tamoxifen sensitivity, ER stability in
absence of E2 [31,55]
None N/A N/A N/A
S118
Phosphorylation
(CDK7, ERK1/2, IKKα,
GSK3β, ILK, EGFR, IGF1R, DNA-PK, RET)
Increased stability [48] None N/A N/A N/A
S167 Phosphorylation(p90, RSK1, S6 K1, Akt, IKKε, CK2) Inhibits proteasomal degradation [30] None N/A N/A N/A
K171 SUMOylation(SUMO3)
Repressed gene transactivation,
antiestrogen sensitivity [56] None N/A N/A N/A
K180 SUMOylation(SUMO3)
Repressed gene transactivation,
antiestrogen sensitivity [56] None N/A N/A N/A
Y219 Phosphorylation(c-Abl)
Enhanced gene transactivation,
increased DNA binding and
dimerisation, rapid cell growth and
increased invasive capacity [54]
None N/A N/A N/A
K235 Methylation(SMYND2) Repressed gene transactivation [44] None N/A N/A N/A
K266
SUMOylation
(SUMO-1) Repressed gene transactivation [57]
None N/A N/A N/AAcetylation
(p300)
Promotes DNA binding and
transactivation capacity [58]
Methylation
(SET7, SMYND2) Repressed gene transactivation [44]
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Table 1. Cont.
Site Posttranslational Modification (Mediator) Effect ESR1 Mutations # ET Resistant Frequency Functionally Tested
K268
SUMOylation
(SUMO-1) Repressed gene transactivation [59]
None N/A N/A N/A
Acetylation
(p300)
Enhances DNA binding and gene
transactivation [60]
S282 Phosphorylation(CK2)
Tamoxifen sensitivity, suppression of
gene transactivation, ER stability [37,61] S282C Unknown 0.3% (1/292) [62] N/A
K299
SUMOylation
(SUMO1, SUMO2/3)
Repressed gene transactivation,
antiestrogen sensitivity [56,57]
None N/A N/A N/A
Acetylation
(p300)
Not major target of acetylation, hinge
lysines are preferentially
acetylated [60,63]
K302
Ubiquitylation
(BRCA1/BARD1)
ER degradation, induced by estrogen or
fulvestrant [52,64]
None N/A N/A N/ASUMOylation
(SUMO-1) Repressed gene transactivation [59]
Methylation
(SET7/9, SMYD2) ER stability, recruitment to promoter [59]
K303
Ubiquitylation (BRCA1/BARD1?) ER degradation, induced by estrogen orfulvestrant [52,64]
K303R
Yes, resistant to
AIs and
tamoxifen [33,65]
49.81% (133/267)
of invasive
BCa [66]
In combination with
S305, promotes
crosstalk with growth
factor pathways,
and confers resistance
to AIs and
tamoxifen [32,33,65]
SUMOylation
(SUMO-1)
Enhances estrogen induced DNA
binding and transcription [52]
Repressed gene transactivation [57]
Acetylation
(p300)
Represses ER transactivation
activity [63]
S305 Phosphorylation(PAK1, PKA)
Tamoxifen resistance
In the presence of the K303R mutation,
enhances crosstalk with IGF-1/IRS/Akt
pathway and aromatase inhibitor
resistance [33–35,61,67]
None N/A N/A N/A
C447 Palmitoylation(DHHC-7, DHHC-21) Membrane localisation [68] None N/A N/A N/A
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Table 1. Cont.
Site Posttranslational Modification (Mediator) Effect ESR1 Mutations # ET Resistant Frequency Functionally Tested
C451 SUMOylation(SUMO3)
Sensitivity to fulvestrant and tamoxifen,
through gene repression [69] None N/A N/A N/A
K472 SUMOylation(SUMO3)
Repressed gene transactivation,
antiestrogen sensitivity [56] None N/A N/A N/A
V534 Ubiquitylation(E6-AP ligase)
ER degradation, induced by estrogen
Subcellular localisation, gene
transactivation and the degradation of
the ER [70]
V534E Unlikely
1/616 (0.16%)
metastatic
BCa [25]
No effect, neither
constitutively active nor
inactivating [25]
Y537
Ubiquitylation
(E6-AP ligase)
ER degradation, induced by estrogen
Subcellular localisation, gene
transactivation and the degradation of
the ER [70]
Y537C Yes
6/616 (0.97%)
metastatic
BCa [25]
Ligand independent,
somewhat resistant to
tamoxifen, fulvestrant
and estrogen
deprivation [25,71]
Phosphorylation
(SRC)
Regulation of subcellular localisation,
transcriptional activity and degradation
of the ER [25,45]
Y537D Unknown
1/616 (0.16%)
metastatic
BCa [25]
Estrogen independent,
increased activation of
progesterone
receptor [25]
Y537H Unknown 1/56 (1.79%)cfDNA [72] N/A
Y537N Yes
5/616 (0.81%)
metastatic
BCa [25]
Ligand independent,
relatively resistant to
tamoxifen, fulvestrant
and estrogen
deprivation [25,71]
Y537S Yes
13/616 (2.11%)
metastatic
BCa [25]
Constitutively active,
adopts conformation
that enhances
coactivator binding,
requires much higher
concentrations of
fulvestrant for
inhibition of ER
activities than WT [25]
S573 Glycosylation(GALNT6)
Nuclear localisation, gene
transactivation [41] None N/A N/A N/A
# reported mutations in breast cancer.
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The wildtype (WT) K302/K303 ER sites stabilise ligand-free ER and estrogen-mediated ubiquitylation
and increase ER transactivational capacity through nuclear translocation. Within the hinge region of
the ER, between amino acids K299 and K303, is the nuclear localisation sequence. This sequence is
also essential for polyubiquitination and degradation induced by fulvestrant. Mutagenesis of K302 and
K303 to alanine (K302R and K303R) result in a disruption to the nuclear localisation sequence [16].
Additionally, lysines central to ubiquitin binding are removed, which causes reduced ER degradation
thus, confirming their role in regulating ER stability and antiestrogen resistance [52]. The K302R and
K303R mutants are resistant to ubiquitylation by breast cancer type 1 susceptibility protein (BRCA1),
hence promoting ER stability [73] and opposing fulvestrant induced degradation [52]. However, some
data suggest that BRCA1/BRCA1 associated RING domain 1 ubiquitylates K302/K303 mutant ER at
alternative, nearby lysines instead lead to a reduced rate of degradation compared to WT [64].
The Y537 site, although not a lysine, is also important in ubiquitylation and subsequent degradation.
In response to estrogen binding, ER associates with the proto-oncogene tyrosine-protein kinase Src
(SRC). SRC phosphorylates the ER at various sites, including Y537 [70]. Y537 phosphorylation favours
interaction of ER with E6-AP ligase, enhancing ER binding to target promoters [70]. Following ER
driven gene transcription, the E6-AP ligase polyubiquitylates the ER targeting it for degradation [70].
Mutagenesis to Y537F results in reduced interaction with the E6-AP ligase, reduced transactivation of
ER target genes, including GREB1 and pS2, and increased stability [70]
3.2. SUMOylation
Small ubiquitin-related modifier 1 (SUMO-1), shares structural similarities with ubiquitin and
has a similar mechanistic pathway, involving activating, conjugating and ligase enzymes. Despite
this, SUMO-1 has distinct functions to ubiquitin. The SUMO pathway regulates transcription, nuclear
transport, cell growth, proliferation, apoptosis, and protein stability and activity, which are important
cellular processes in carcinogenesis [57]. The SUMOylation pathway relies on the actions of activating
(SUMO Activating Enzyme), conjugating (ubiquitin-conjugating enzyme E2) and ligase enzymes
(protein inhibitor of activated STAT) [57]. Whilst the ER lacks the classical ΨKXE SUMOylation site,
SUMOylation at lysines K171, K180, K266, K268, K299, K302, K303, and K472, within the hinge region,
has been reported [56,57] (Table 1).
ER SUMOylation regulates the transcriptional activity of the receptor in response to estrogen
and tamoxifen. Treatment with estrogen and with tamoxifen enhances SUMOylation required for
transcriptional activity. In a study by Sentis et al. mutation of ER lysine to arginine mutations at
several positions (K266, K268, K299, K302, and K303) significantly reduced SUMOylation and gene
transactivation. However, in that study, several mutations were investigated simultaneously, which
explains why the effects of individual lysine to arginine mutations were not assessed [57].
SUMOylation is required for fulvestrant induced transcriptional repression, and is associated
with recruitment of corepressors and reduced chromatin accessibility [56,69]. In the presence of
fulvestrant, SUMOylation may only allow transient DNA binding of the receptor, reducing overall
transcription [69]. However, another study suggested that fulvestrant induces SUMOylation at K171,
K180, K99, K472 sites. Furthermore, mutagenesis of L539A or L540A reduces this SUMOylation and
hence promotes gene transcription in the presence of antiestrogens [56]. This notion is supported by
the fact that the ET-resistance ER mutation V534E, which prevents SUMOylation, also enhances ER
dependent gene transcription in the presence of fulvestrant [69]. Therefore, SUMOylation may be
required for the effect of antiestrogens, and can be influenced by mutations in the LBD of the ER.
3.3. Phosphorylation
Phosphorylation is a common PTM regulating the activity of the ER, with various kinases
phosphorylating approximately 20 ER sites. ER phosphorylation affects ligand binding, DNA binding,
dimerisation, transcription, coactivator binding, protein stability, subcellular localisation, interactions
with other PTM effectors, and cell growth and invasion [74]. Here, we focus on those involved
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in ER stability and ET resistance or occurring at sites of ESR1 mutations: Y52, S104, S106, S118,
S167, Y219, S282, K303, S305, and Y537 (Table 1). Many studies have investigated the effects of ER
phosphorylation, using mutagenesis to change amino acids at serine or tyrosine phosphorylation sites
to either prevent (mutagenesis to alanine or phenylalanine, respectively) or mimic (serine to glutamic
acid) phosphorylation. The data support the premise that S104, S106, and S118 phosphorylation is
essential for ER transactivational activity. Moreover, alanine substitution inhibits, whilst a change with
glutamic acid enhances, ER target gene transcription, compared to WT [31]. At ER S167 and S118
sites, phosphorylation loss results in increased growth and migration/invasive capacity, distinct gene
expression patterns, and a reduction in apoptosis, in MCF-7 cells [75]. S167 phosphorylation, however,
stabilises ER. In the presence of the protein synthesis inhibitor, cycloheximide, in 293T cells ectopically
expressing ER S167A, its levels were reduced compared to ectopic WT ER. MG132 restored ER levels
in S167A mutant expressing cells, demonstrating regulation of stability by the UPS [30].
ER S118A and S118E mutants on the other hand were more stable than WT ER, and S118E displayed
higher transcriptional activation capacity, whilst S118A reduced gene transcription, compared to WT.
This suggests that the S118 site has mechanistically distinct roles in regulating ER degradation and ER
transcriptional activity [76]. Following estrogen exposure and subsequent gene transcription, a portion
of the total receptor pool are ubiquitylated leading to degradation; this response is rapid, occurring
within the first 24 h [48]. Meanwhile, another portion of ER is phosphorylated at S118, effectively
preventing ubiquitination and thus degradation. Thus, over time, 24–72 h post estrogen addition,
the rate of proteolysis decreases [48]. Thus, the S118 site of ER maybe central to controlling the tight
balance of activity and protein turnover.
Phosphorylation at Y52 and Y219 ER sites by c-Abl individually enhances gene transcription and ER
stability [54]. Y219 phosphorylation also promotes DNA binding and dimerisation [54]. Mutagenesis of
these sites (Y52F and Y219F) causes a reduction in cell number and invasive capacity [54]. Interestingly,
c-Abl also inhibits the proteasome, through phosphorylation of a subunit known as PSMA7, and thus
may reduce ER degradation [54]. c-Abl extends the half-life of the ER from 6 h (c-Abl inhibited) to 12 h
(c-Abl active), with no observable change in the mRNA levels of ER [54]. Likewise, inhibition of the
26S proteasome by MG132 extends the half-life of ER, even after c-Abl inhibition [54].
Phosphorylation also regulates tamoxifen response. The effect of tamoxifen on the ER is context
dependent in that it can either block ER (antagonist) in breast tissue and it can promote ER activity
(agonist) in other tissues through activation of AF-1 [77]. For instance, phosphorylation of S104,
S106 and S118 promotes tamoxifen agonist activity in the breast [31]. COS-1 cells expressing S106E,
mimicking phosphorylation, had greatest activity followed by S104E and S118E, in the presence of
tamoxifen [31]. Meanwhile, phosphorylation of the S282 site is thought to contribute to tamoxifen
sensitivity. Patients treated with tamoxifen with phosphorylated S282 ER had longer progression
free survival (PFS) and overall survival (OS) than patients lacking phosphorylation at this site [37].
The phosphorylation at S282 also plays an important role in ER stability. COS-1 cells ectopically
expressing ER S282A mutant displayed reduced mutant ER levels at 24 h, but not as early as 3 h,
of estrogen exposure, compared to WT ER expressing cells [61].
The S305 ER site is phosphorylated by protein kinase A (PKA) and p21-activated kinase 1 (PAK1),
and, in some cases, by Aurora Kinase A and AKT [33,67,78,79]. Phosphorylation of S305 in K303R
ER mutants enhances interaction with insulin-like growth factor 1 (IGF-1) and is associated with
constitutive phosphorylation of IGF-1 and insulin receptor substrate (IRS); promoting cell growth [33].
This cell growth is reduced by inhibiting IGF-1 receptor (IGF-1R) with the tyrosine kinase inhibitor,
Tyrphostin AGTreatment with both the AI substrate androstenedione and IGF-1 resulted in greater
growth of K303R mutant cells, than with either of these ligands independently [33]. These data provides
further evidence of the crosstalk between K303R ER and the IGF-1/IRS/AKT pathway and suggest that
phosphorylation of S305 plays critical roles in ER protein interactions and in AI resistance [33].
ER S305 phosphorylation by PKA and PAK1 is associated with tamoxifen resistance and is a
potential predictive marker of tamoxifen treatment response [34,35,80]. S305 phosphorylation causes
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tamoxifen bound ER to remain in its active conformation, thereby promoting resistance [35]. Indeed,
BCa patients with tumours that had nuclear PAK1 expression and phosphorylated ER S305, had
significantly reduced responses to tamoxifen; nuclear expression of phosphorylated ER S305 was
observed in 36% of patients and showed a trend towards reduced tamoxifen response [80]. However as
less than 10% of tumours had both phosphorylated ER S305 and nuclear PAK1 expression, this suggests
some redundancy and other kinases, such as PKA, may also be involved in the phosphorylation of ER
S305 [80]. It was proposed that PKA phosphorylates tamoxifen bound ER at the S305 site, and this alters
its conformation such that the coactivator SRC can facilitate transcription factor complex assembly and
localisation to target promoters, to enable gene transcription in the presence of tamoxifen [67]. Indeed,
activation of PKA through the down regulation of a negative regulator of PKA, known as PKA-Riα,
was predictive of tamoxifen resistance and resulted in a growth stimulatory effect in the presence of
tamoxifen, interestingly not observed when treated with fulvestrant [35]. These studies suggest that
phosphorylation of ER S305, by either PKA or PAK1, is linked with resistance to tamoxifen and AIs.
The Y537 site is phosphorylated by SRC, following ER ligand binding. As outlined above, p-Y537
attracts E6-AP ubiquitin ligase, promoting transactivational activity and ultimately degradation, linking
these PTMs functionally [70]. ER Y537 phosphorylation promotes cytoplasmic localisation, however, is
associated with increased proliferation [81]. While it remains counterintuitive that cytoplasmic p-Y537
ER increases proliferation, it was speculated that proliferation occurs as a result of growth signaling
pathway interactions which promote cell cycle progression [81]. Indeed, there is evidence that p-Y537,
while less transcriptionally active, cooperates with phosphorylated SRC to drive proliferation via
the AKT pathway and downstream cyclin D1 upregulation [81]. In MDA-MB-231 cells ectopically
expressing ER Y537F, ER is retained in the nucleus, preventing its extranuclear activities [70]. There, ER
Y537F is stabilised likely due to a lack of E6-AP interaction needed for proteasomal degradation within
the nucleus [70] These data highlight the importance of Y537 in ER regulation and may help explain its
frequency as AI resistance associated ER mutations. Further study is needed to fully elucidate the
effects of p-Y537 and the effects of loss of this functional PTM via amino acid substitutions.
One resistance associated change is Y537S, and the substituted serine may be a target of
phosphorylation but that has not been investigated to-date. One study, however, observed increased
S118 phosphorylation for ER Y537S mutants [82], associated with increased ER stability [48].
It is evident that a large proportion of ER phosphorylation is mediated by kinases belonging
to the PI3K-AKT-mTOR and MAPK pathways, mentioned earlier in the context of non-genomic ER
signaling. Signaling through these pathways abrogates the necessity for ER binding and contributes
to ET resistance. For example, phosphorylation of S167 on K303R mutated ER by AKT, leading
to aromatase inhibitor resistance [30,32]. Phosphorylation of ER at S167 by AKT has also been
shown to promote ER stability and activate ER mediated transcription in an estrogen independent
manner [30,32,83]. Furthermore, ER Y537 phosphorylation by SRC promotes promoter occupancy
and gene transcription [70]. These studies demonstrate estrogen independent ER signaling through
crosstalk mediated by kinases. Later, potential therapeutics targeting these resistance mechanisms
are discussed.
3.4. Palmitoylation
Palmitoylation of the ER is important for its stabilisation and localisation. Palmitoylation at C447
drives the association of ER with caveolin-1, which results in membrane localisation and favours
non-genomic ER actions (see above) [84]. ER-estrogen interaction promotes removal of palmitoyl
groups, the dissociation of caveolin-1, and hence nuclear localisation and ultimately degradation [43,84].
Inhibition of palmitoylation, with 2-bromo-hexadecanoic acid or by C447A mutation, increased ER
degradation at all time points investigated, up to 8 h post estrogen treatment [43]. Interestingly, this
resulted in reduced ER stabilising S118 phosphorylation, further highlighting relationships between
different PTMs at various ER sites [43,48].
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3.5. Acetylation
Acetylation of the ER occurs within the hinge and LBD region, by the actions of p300/CREB-binding
protein at the sites K266, K268, K299, K302, and K303 (Table 1) [60,63]. The effect of acetylation varies
dependent on the site. Acetylation at K266 and K268 promotes DNA binding and transactivation
capacity [60]. Conversely, acetylation at K302 and K303 represses ER transactivation activity [63].
Phosphorylation at S305 site prevents the acetylation at K303 [33] in turn hypersensitising the ER
to estrogen [85]. The ER K303R change, identified in both breast hyperplasia and BCa tissue [66,86]
therefore confers estrogen hypersensitivity and prolongs ER stability.
3.6. Methylation
Methylation occurs on lysine residues and is catalysed by the histone lysine methyltransferases
SET7 and SET and MYND domain containing 2 (SMYND2). SET7 methylates ER at K302 and thereby
enhances ER stability, mediates target promoter recruitment and directly competes with ubiquitination,
which increases ER stability [59]. ER lysine methylation may also promote interaction with proteins,
such as calmodulin, indirectly preventing ubiquitylation mediated by E6-AP also increasing ER
stability [59].
The ER hinge region enables the coordination of multiple PTMs in response to the presence/absence
of estrogen. For example, K266 methylation and acetylation is dependent on estrogen levels. K266
methylation by either SET7 or SMYND2 represses transactivation activity by preventing ER chromatin
recruitment in the estrogen deprived setting [44]. Upon estrogen binding, K266 is demethylated by
histone H3K4 demethylase lysine-specific demethylase 1 [44]. Subsequently, p300/CBP acetylates
the ER, permitting chromatin recruitment and gene transcription [44]. K235 is also methylated
by SMYND2, in the absence of estrogen, acting to repress gene transcription. Crosstalk between
methylation and acetylation at this site is mediated by the transcriptional coactivator euchromatin
histone methyltransferase 2, which recognises demethylated K235 [87]. This results in recruitment of
the ‘PHD finger protein’/’males absent on the first’ complex, which is responsible for the acetylation of
the ER and results in transcriptional activity [87].
3.7. Glycosylation
Glycosylation of S573, facilitated by a polypeptide known as N-acetylgalactosaminyltransferase
6 (GALNT6), promotes nuclear localisation, transcriptional activity and stability of the ER (Table 1).
In T47D and MCF-7 cells, siRNA knockdown of GLANT6, results in reduced ER nuclear localisation
and expression of ER target genes (MYC, CCND1 and CTSD) and this was generally irrespective
of estrogen presence [41]. Hence, S573 glycosylation by GLANT6 is an important regulator of ER
localisation and transcriptional activity [41].
4. Clinical Relevance
ER signaling remains central to the treatment of ER positive BCa, and PTMs play a significant role in
determining responses to ET, alongside ESR1/ER mutations. Table 1, outlines the functions of common
ER PTMs, including phosphorylation, acetylation, ubiquitylation and SUMOylation, and known
ESR1/ER mutations at these sites. Resistance mechanisms to ET are complex, and likely involve
changes to number of pathways with ER at a central hub. While ER PTMs and their dysregulation due
to mutations would affect the interactions of ER with several signaling pathways, including growth
signaling and proteasomal degradation pathways, this presents an opportunity whereby combination
therapies with drugs targeting these pathways may help to re-sensitise tumours to ET.
4.1. Estrogen Receptor Mutations and Resistance
Several ESR1 mutations have been identified. The general consensus is that these mutations
may cause conformational changes that affect drug binding and/or ER activity. For this review it is
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important to emphasise that four key mutation sites are also sites of PTMs, namely S282C, V534E,
K303R and Y537C/N/S, described below (Table 1).
4.1.1. S282C
The S282C ESR1 mutation was identified in a single BCa tumour [62]. Functionally, the effect of
this mutation has not been tested, but p-S282 has been proposed to inhibit ligand dependent activation
of the ER. The S282A ER mutation prevents phosphorylation and increases ligand independent
transcriptional activity compared to WT [61]. The S282C mutation detected in a patient’s tumour tissue
would likely also prevent phosphorylation and increase ligand independent ER transactivation activity.
Due to its rarity, the clinical relevance of this mutant, however, may be minimal.
4.1.2. K303R
The K303R ESR1 mutation was first identified in breast typical hyperplasia patients, with a
frequency of 34% in (20/59) of ET resistant BCa patients [86]. In invasive BCa, K303R was detected in 50%
(133/267) of patients and was associated with reduced 10-year recurrence free survival, larger tumour
size and lymph node involvement [66]. Functional testing showed that ER K303R is hypersensitive to
estrogen, binds to PI3K to promote growth and survival via the PI3K/pathway, and in combination
with p-S305, promotes signaling through the IGF-1R/IRS-1/AKT pathway. It is through these pathways
that the K303R mutation may promote resistance to tamoxifen and anastrozole [32,33,65]. The effect of
K303 is mediated by PTMs and connected to other posttranslational events as the phosphorylation of
S305 inhibits acetylation of K303 resulting in ER inhibition [85]. Some of these functional changes may
be based on the K303 site being a common PTM site for ubiquitylation, SUMOylation and acetylation,
dependent on the context. Thus, a substitution from lysine to arginine at position 303 likely has
important implications for ER activity.
4.1.3. Y537C/S/N
There are number of mutations identified at Y537, including Y537C, Y537D, Y537H, Y537N,
and Y537S [25,45]. P-Y537 is critical to control ligand binding, DNA binding, dimerisation, transcription,
coactivator binding, protein stability, subcellular localisation, interactions with other PTMs, and cell
growth and invasion [58]. Y537N and Y537S were detected in 13.89% of biopsies from patients with
hormone resistant tumours and accounted for over half of all detected ESR1 mutations [24]. Y537S
confers resistance to fulvestrant treatment, and is associated with reduced PFS, and occurs at a higher
frequency following fulvestrant treatment 8.7% (17/195) compared to 1.5% (3/196) in advanced BCa
patients [88]. In another study, ESR1 mutations were detected in CTCs exclusively from patients
treated with estrogen deprivation therapy, and of the 13 patients with ESR1 mutations detected in
CTCs, 23% (3/13) had Y537C/N mutations [89]. The outlined importance of PTMs at the Y537 site
suggests that ESR1 Y537 mutations may at least in part cause resistance by affecting ubiquitylation and
phosphorylation and the connected molecular outcomes of these PTMs.
4.2. Other PTM Sites and Resistance
S167 and S118
Several studies have investigated the effect of phosphorylation at S167 and S118 and the
resulting sensitivity to tamoxifen. Reports with regard to p-S167 are conflicting with some studies
observing no association, some reporting trends of association and others showing correlation, between
phosphorylation loss and tamoxifen resistance [90–93]. The effect p-S118 site is also controversial.
In patients with primary tumours expressing p-S118, it was reported that tamoxifen treatment assured
longer disease-free survival (DFS) and a trend towards better OS [94]. Conversely, another study
demonstrated that patients whose primary tumours were positive for p-S118 had significantly shorter
DFS and OS after treatment with tamoxifen [91]. Low phosphorylation levels at S118 was associated
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with improved DFS and OS [63] and elevated p-S118 levels were associated with relapse following
tamoxifen treatment [95]. Interestingly, another study investigated the effect of the S118P variant on
endocrine response and found no significant difference in response to either tamoxifen or fulvestrant [96].
Whilst these studies may differ in patient cohorts and methods, it is possible that the effect of the
phosphorylation is context dependent and may relate to other PTMs and pathways. A number of
studies have observed tamoxifen resistance in association with p-S305 in both in vitro studies and in
patient cohorts [97,98].
4.3. Treatments
Treatment of metastatic ER positive BCa is challenging with 30 of patients developing resistance
to ET [22,23]. Therapy options for these patients can be broadly categorised into one of three groups,
based on their targets: (i) those specifically targeting the ER, (ii) those targeting ER signaling pathways,
and (iii) those targeting alternative pathways [99]. Treatment can be a monotherapy or a combination
of drugs from these different categories, targeting mutated ER, degradation (proteasome inhibitors),
or kinase pathways (Table 2).
Table 2. Current and Potential Therapeutic Targets in Breast Cancer.
Treatment Target Experimental/ClinicalTrial/Current Treatment Outcome/Conclusion
Aromatase Inhibitors
(Anastrozole,
Exemestane, Letrozole)
Aromatase Current
The proliferation marker, Ki67, was significantly
suppressed by anastrozole (76%) after 2 weeks of
treatment compared to tamoxifen (62%) and the
combination (64%) [12]
Tamoxifen ER (SERD) Current 5-yr adjuvant tamoxifen use results 47%reduction in recurrence [12]
Fulvestrant ER (SERM Current Greater suppression of ER, PgR and Ki-67 wasobserved in the higher dose fulvestrant [12]
Cyclin-dependent kinase
4/6 inhibitors (CDKIs)
Cyclin-dependent
kinase 4/6 Current
CDKI treatment in combination with ET extends
PFS by a median of 8.8 months [100]
H3B-5942 ER (SERCA) Experimental
Greater antiproliferative effect than fulvestrant.
Has synergistic effect when combined with
CDK4/6 and mTOR inhibitors [101]
AZD9496 ER Trial Disease stabilisation [25,102–104]
Bortezomib Proteasome inhibitor Experimental Inhibit cell growth of both ER+ and ER-cells [49–51]
FK228 Histone deacetylaseinhibitor Trial
Combined with vorinostat and tamoxifen results
in tumour regression [105,106]
Vorinostat Histone deacetylaseinhibitor Trial Show tumour regression with FK228 [106]
Capivasertib AKT inhibitor Trial
Patients who received capivasertib plus
fulvestrant had a median PFS of 10.3 months
compared to 4.8 months in patients who received
a placebo plus fulvestrant, warranting further
investigation, in a phase III trial [107]
Alisertib Aurora Kinase Ainhibitor Trial
In combination with fulvestrant demonstrated
anti-tumour activity [108]
FRAX1036 PAK1 inhibitor Experimental Acts synergistically with alisertib with greaterefficacy [109]
Dasatinib SRC and AbI inhibitor Experimental In combination with letrozole was promising in71% of patients [110]
Saracatinib (AZD0530) SRC inhibitor Experimental
In combination with fulvestrant had a greater
effect at reducing proliferation than
alone [111,112]
Bosutinib SRC inhibitor Experimental Had an unfavourable risk-benefit ratio [113,114]
4.3.1. Targeting ESR1 Mutants
Currently, drugs targeting the ER are categorised as either SERDs or SERMs. Many patients
treated with monotherapies of fulvestrant or tamoxifen, for example, develop resistance, in part due to
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acquired ESR1 mutations. Novel therapy options for these patients are arising including a novel drug,
H3B-5942, which falls into a new ER target category coined “Selective Estrogen Receptor Covalent
Antagonists” [101]. H3B-5942 covalently binds to the ER cysteine at position 530, which is located
within helix 11 in the ligand binding pocket. ER mutations, at Y537 and D538, are known to stabilise the
agonist conformation of the ER [101]. However, upon binding of H3B-5942 an antagonist conformation
is adopted, regardless of the presence or absence of the Y537S or D538G ESR1 mutation [101]. Compared
with fulvestrant, H3B-5942 has a greater antiproliferative effect and increased the suppression of ER
target genes [101]. Additionally, CDK4/6 inhibitors and mTOR inhibitors, have a synergistic effect when
combined with H3B-5942, resulting in greater antiproliferative effects than monotherapy alone [101].
A novel SERD, known as AZD9496, showed anti-tumour activity of AZD9496 in the ESR1 Y537S
mutant in in vitro models, with greater potency than fulvestrant [25,104]. It was also effective in a
CTC-174 ER positive BCa patient derived xenograft (PDX) model with the D538G ESR1 mutation [104].
In a phase I clinical trial for the treatment of ER+/HER- BCa with AZD9496 patients, there was evidence
of prolonged disease stabilisation, with good drug tolerability by patients [102]. These data suggest,
that AZD9496 may be an effective treatment option for BCa patients with Y537S and D538G mutations.
However, in a window-of-opportunity presurgical study, treatment with AZD9496 for two weeks was
not superior to fulvestrant at the dose tested [103].
4.3.2. Clinical Proteasomal Inhibition
Proteasome subunits are frequently upregulated and exhibit increased activity in a variety of
cancers including BCa [115]. A proteasome inhibitor, bortezomib, has been FDA approved for the
treatment of multiple myeloma [116] and several studies are currently investigating its therapeutic
potential of in ER positive BCa.
Short-term exposure to bortezomib has been shown to increase ER stability. However, chronic
exposure to proteasome inhibition results in reduced transcription of ESR1 [49–51]. Bortezomib is
thought to cause chromatin changes of a distal enhancer region of ESR1 reducing its transcription
and consequently ER accumulation [50]. Another study observed a downregulation of ER, Erb-B2
Receptor Tyrosine Kinase 2 (HER2), and epidermal growth factor receptor (EGFR) expression that led
to a reduction in PI3K-Akt, mTOR, and MAPK signaling [117].
Bortezomib also inhibits cell growth in ER BCa positive cell lines, by increasing mRNA levels
of the cyclin dependent kinase inhibitor (CDKI), p21, causing cell cycle arrest [118]. Interestingly,
silencing of the ER prevented the effects of bortezomib, suggesting that ER is required for this p21
regulation [118]. In MCF-7 cells, the combination of bortezomib and tamoxifen inhibited cell growth
by 70% [118].
As a proteasome inhibitor, bortezomib has the potential to affect many protein types, and how
this contributes to treatment response or toxicity is largely ill defined. The drug was well tolerated in a
single agent clinical trial in metastatic BCa patients but had little beneficial effect [119]. Multiple studies
have demonstrated that combination therapy of bortezomib and SERDs are effective in the treatment
of BCa, including in the ET resistant setting. A randomised phase II trial with the combination
of fulvestrant and bortezomib for the treatment of AI resistant metastatic BCa found significantly
improved PFS (28.1%), compared to fulvestrant alone (13.6%), despite the median PFS remaining
similar. Patients who progressed on fulvestrant alone, were able to change to the combination arm,
and in this group PFS was at 18% for a minimum of 24 weeks [120].
Fulvestrant causes the accumulation of newly synthesised ER aggregates in the cytoplasm. In the
presence of bortezomib, these aggregates are not degraded and hence build up within the cytoplasm,
leading to the initiation of what is described as the “proapoptotic unfolded protein response”, leading to
cell death [121]. For any treatment, identification of patient groups that are likely responders is essential;
one study identified a proteasome signature which was associated with poorer patient outcomes
and demonstrated that MCF10A cells expressing this signature were susceptible to Bortezomib
treatment [116].
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4.3.3. Targeting Kinases
ER p-S305 is strongly associated with ET resistance. This site is phosphorylated by PAK1, PKA,
Aurora Kinase A or AKT [33,78] and overexpression of PAK1 and PKA is associated with poorer
patient outcomes in BCa. Additionally, both PAK1 and PKA induced S305 phosphorylation are strongly
correlated with reduced time to progression. Patients with p-S305 progressed in nine months, compared
with 18 months seen in patients without PAK1/PKA associated S305 phosphorylation [97]. The ESR1
K303R mutation, which is associated with tamoxifen and AI resistance, increases the efficiency of S305
phosphorylation [32,33,78]. As this site may be phosphorylated by three different kinases, targeted
therapy could be challenging, but may also provide the opportunity to target based on context. Several
studies have demonstrated that inhibiting S305 phosphorylation, in in vitro and in xenograft models,
may re-sensitise ET-resistant tumour cells to ET and cause increased apoptosis.
A clinical trial has investigated the combination of alisertib with fulvestrant as a therapeutic
option for BCa patients [108]. Alisertib is a drug which targets Aurora Kinase A, which is another
kinase associated with ET resistance and which phosphorylates the ER at S305 [79]. In a phase I study,
the combination of alisertib and fulvestrant had a positive anti-tumour activity, in ET resistant patients,
which had been previously treated with tamoxifen and AIs. A six-month clinical benefit rate was
achieved in 77.8% of patients [108].
FRAX1036 is PAK1 inhibitor and has been combined with Alisertib with promising results in
a range of BCa cell lines, and in BT474 xenograft models. The combination acts synergistically, to
inhibit growth and ER signaling and reduces cell survival and its greatest efficacy was observed in
hormone receptor positive/HER2 positive BCa cell lines [109]. Furthermore, it was observed that this
combination inhibits phosphorylation of ER S305 and S118 in BT447 and T47D cell lines, and prevents
PAK1 and ER signaling in BT474 xenograft models [109].
PAK1 activation can be blocked by the histone deacetylase inhibitor, FK228, which suppresses
estrogen dependent growth in MCF-7 cells, and blocks growth in tamoxifen sensitive and resistant
xenograft models [105]. Other histone deacetylase inhibitors have shown promising results in treating
ET resistant BCa including a phase II study where 40% of patients resistant to AIs achieved tumour
regression or disease stabilisation in response to the combined treatment with histone deacetylase
inhibitor, vorinostat, and tamoxifen [106].
As mentioned previously, AKT can phosphorylate S305, in the presence of K303R. Given the
significant crosstalk between the PI3K/AKT pathway and the ER, it could be a potential therapeutic
target. In a phase II study, an AKT inhibitor, capivasertib, was tested in combination with fulvestrant
in patients who had progressed on AIs. Patients who received capivasertib plus fulvestrant had a
median PFS of 10.3 months compared to 4.8 months in patients who received a placebo plus fulvestrant,
warranting further investigation in a phase III trial [107].
4.3.4. Targeting Coactivators
Another approach to the treatment of ET resistant BCa is to identify druggable targets in the
resistance pathways. ER Y537S and D538G expressing BCa cells are reliant on SRC activity. Unlike
WT, these ER mutants can bind the coactivator SRC, even in the absence of estrogen [96,122]. As such,
SRC inhibition may be an effective therapeutic option. The combined treatment with a SRC inhibitor,
SI-1, and the SERD AZD9496 resulted in a significant reduction in tumour volume compared with
monotherapy and controls, in a PDX ER Y537S expressing mouse model [122].
Several studies have also investigated SRC inhibitor potential in ET resistant BCa, particularly
combination with AIs or SERDs. The combination of the AI, letrozole, and the SRC inhibitor dasatinib
resulted in a clinical benefit rate (the percentage of patients with complete response, partial response
or stable disease ≥6 months) of 71% for patients treated with the combination, 66% for those treated
with letrozole alone and 23% for those that progressed on letrozole alone and crossed over to the
dasatinib/letrozole combination [110]. It was proposed that the addition of dasatinib may delay
resistance to letrozole [110].
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Saracatinib (AZD0530), another SRC inhibitor, may also be effective in combination with ET,
such as fulvestrant or AIs. The combination of saracatinib with fulvestrant reduced proliferation
and to a greater extent than either drug alone in both MCF-7Arom5 cells, which express aromatase,
and xenograft mouse models, suggesting a synergistic effect [111]. The combination of saracatinib
and anastrazole achieved greater cell cycle arrest than either drug alone, and in xenograft models had
greater antitumour activity, supporting further clinical investigation [112].
5. Conclusions
The ER and its signaling remain central to BCa treatment and ET resistance poses significant
challenges. Since PTMs significantly modify ER functions, including protein interactions, subcellular
localisation, estrogen sensitivity, transactivation capacity, and stability, amino acid substitution
mutations altering PTM sites may dramatically change ER effects and responses to ET. The S282,
K303, and Y537 sites play key roles in ER regulation and are sites of ESR1 mutations associated with
ET resistance. Mutations at these sites will prevent ubiquitination (K303 and Y537), SUMOylation
(K303), phosphorylation directly (S282, Y537, and indirectly at S305), and acetylation (K303). Here,
we reviewed ample evidence that these changes affect ER function and half-life and ultimately change
the response to ET. This review has highlighted the factors contributing to ET resistance and promising
therapeutic options for the treatment of ET resistant BCa, particularly in patients with ESR1 mutations.
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